TNM Cancer Staging Manual 5.0.11

"Try before you buy" - Download the FREE App, which includes sample content. In-App purchase required to unlock all content.

The TNM Cancer Staging Manual is widely recognized as the definitive reference for medical professionals worldwide in the field of oncology. This invaluable mobile resource provides Interactive TNM calculators to facilitate accurate cancer classification and staging.

• Breast cancer
• Colon and Rectum
• Distal Bile Duct
• Liver
• Neuroendocrine Tumors
• Perihilar Bile Ducts
• Stomach + Many others

FULL DESCRIPTION:

The TNM Cancer Staging Manual is an essential tool used by physicians, surgeons, pathologists, radiologists, cancer registrars, and other medical professionals worldwide. It ensures that healthcare providers involved in the care of cancer patients are equipped with comprehensive knowledge of cancer staging terminology.

The proper classification and staging of cancer are vital for determining appropriate treatment, evaluating treatment outcomes and clinical trials, and serving as a global standard for reporting cancer incidence and prognosis.

This updated edition of the manual features significant expansions and developments. It includes 12 entirely new staging systems, a range of revised or new staging definitions, and an enhanced emphasis on personalized-medicine approaches.

Key features of the update include:

• General staging rules for clinical and pathological classifications
• Staging systems in several chapters
• Clear organization of T, N, M, and additional categories into groups
• Histologic classifications and grading systems
• WHO histology codes
• Additional illustrations
• Extensive updates to Cervix Uteri

New paradigms introduced in this edition:

• Human papillomavirus (HPV): oropharyngeal carcinoma staging systems based on HPV status
• Separate staging systems for patients with neoadjuvant therapy (esophagus and stomach)

New features of this edition:

• Levels of evidence provided for revisions to staging systems
• Imaging section
• Risk Assessment Models for select cancer sites
• Recommendations for Clinical Trial Stratification
• Prognostic factors
  -- Required for prognostic stage grouping
  -- Recommended for clinical care
  -- Emerging factors

New topics and staging systems included:

• Risk Assessment Models
• Cervical Nodes and Unknown Primary Tumors of the Head and Neck
• Oropharynx, HPV-Mediated (p16+)
• Cutaneous Carcinoma of the Head and Neck (includes cutaneous carcinoma of external lip)
• Thymus
• Bone: Appendicular Skeleton/Trunk/Skull/Face, Pelvis, and Spine
• Soft Tissue Sarcoma of the Head and Neck, Trunk and Extremities, Abdomen and Thoracic Visceral Organs, Retroperitoneum, Unusual Histologies and Sites
• Parathyroid
• Leukemia

For easy access to this important information, you can choose the method that suits your needs. Whether you access it tomorrow or six months from now, the information will be readily available.

ISBN 10: 3319406175
ISBN 13: 9783319406176

SUBSCRIPTION:

To gain access to the content and receive updates, please consider purchasing a yearly auto-renewing subscription.

Yearly auto-renewing payments: $79.99

Payment will be charged to your iTunes Account at confirmation of purchase. The subscription will automatically renew unless auto-renew is turned off at least 24-hours before the end of the current period. You may manage your subscription and disable auto-renewal by going to your device settings and selecting "iTunes & App Store". Any unused portion of a free trial period will be forfeited upon purchase of a subscription, where applicable.

If you have any questions or comments, feel free to contact us via email at customersupport@skyscape.com or by calling 508-299-3000

Privacy Policy - https://www.skyscape.com/terms-of-service/privacypolicy.aspx

Terms and Conditions - https://www.skyscape.com/terms-of-service/licenseagreement.aspx

Editor(s): Mahul B. Amin, MD, FCAP (Editor-in-Chief), Stephen B. Edge, MD, FACS, Frederick L. Greene, MD, FACS, et. al.
Publisher: Springer-Verlag New York, Inc.